PDCD1 and neoplasm: ICIs enhance immune system eradication of tumor cells by blocking immune checkpoint proteins like PD-L1, programmed cell death protein 1 (PD-1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), which act as brakes on immune cells.